Shegrena-Heibla Phenomenon

Sjögren-Hable Phenomenon is a phenomenon in which immunity in adult experimental animals develops to implanted tumor cells. The phenomenon was discovered in 1957 by American immunologist George Sjogrena and his colleagues.

Sjögren and his colleagues conducted experiments on mice that were infected with tumor-causing viruses. They found that after the mice were infected, they developed immunity to the tumor cells. This immunity was not due to a reaction to other antigens such as bacteria or viruses.

Later, American immunologist Carl Habel continued Sjögren's research and discovered that this phenomenon was also observed in rats and other experimental animals. He also discovered that the development of immunity to tumor cells depended on the type of virus that was used to infect the animals.

The mechanism underlying the Sjögren-Hable phenomenon is still unknown. However, it has important implications for understanding the immune response to tumors and could be used in the development of new cancer treatments.

Sjögren–Hable phenomenon (SHF) is an immunological phenomenon in which animals become immune to certain tumors and viruses after infection or transplantation of tumor cells into tissues. This phenomenon was discovered by scientists Victor Sjogrena and Lawrence Bob Habel, who worked at the medical school of the University of Pittsburgh Medical Center. They were amazed to observe that mice injected with tumor cells only developed tumors in some mice and not others. This phenomenon later became known as SHF.

SHF is associated with the formation of antibodies that can cross-react with viral antigens. This means that the virus can be destroyed by antibodies from the immune system by activating virus-destructive mechanisms in the immune system. The antibody plays an important role in this process as it attaches to the viral particle and damages it, which can lead to lysis of the virus.

In many cases, SHF is necessary to successfully combat viral infection and tumor growth. For example, after an initial infection with SARS-CoV-2, some people may develop tolerance to the coronavirus, which may protect them from recurrence.